FDA grants priority review status to Eisai's eribulin NDA

[News]

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

More... (http://www.news-medical.net/news/20100602/FDA-grants-priority-review-status-to-Eisais-eribulin-NDA.aspx)